➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Tralokinumab

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Tralokinumab?

Tralokinumab is an investigational drug.

There have been 13 clinical trials for Tralokinumab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 19th 2018.

The most common disease conditions in clinical trials are Eczema, Dermatitis, Atopic, and Dermatitis. The leading clinical trial sponsors are LEO Pharma, Emma.Guttman, and AstraZeneca.

There are seven US patents protecting this investigational drug and eighty-two international patents.

Recent Clinical Trials for Tralokinumab
A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy SubjectsLEO PharmaPhase 1
Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic DermatitisLEO PharmaPhase 3
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier FunctionProf. Dr. Stephan WeidingerPhase 2

See all Tralokinumab clinical trials

Clinical Trial Summary for Tralokinumab

Top disease conditions for Tralokinumab
Top clinical trial sponsors for Tralokinumab

See all Tralokinumab clinical trials

US Patents for Tralokinumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tralokinumab   Get Started Free Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Get Started Free
Tralokinumab   Get Started Free Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Get Started Free
Tralokinumab   Get Started Free Compositions and methods for treating fibrotic disease eFFECTOR Therapeutics Inc. (San Diego, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.